The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies. However, pharmacologic inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein-DNA interactions. Here, we demonstrate the rapid and potent abrogation of MYC gene transcription by representative small molecule inhibitors of the BET family of chromatin adaptors. MYC transcriptional suppression was observed in the context of the natural, chromosomally translocated, and amplified gene locus. Inhibition of BET bromodomain-promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G 1 arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. Exogenous expression of MYC from an artificial promoter that is resistant to BET regulation significantly protected cells from cell cycle arrest and growth suppression by BET inhibitors. MYC suppression was accompanied by deregulation of the MYC transcriptome, including potent reactivation of the p21 tumor suppressor. Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia. These findings demonstrate that pharmacologic inhibition of MYC is achievable through targeting BET bromodomains. Such inhibitors may have clinical utility given the widespread pathogenetic role of MYC in cancer.
The MYC transcription factor is a master regulator of diverse cellular functions and has been long considered a compelling therapeutic target because of its role in a range of human malignancies. However, pharmacologic inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein-DNA interactions. Here, we demonstrate the rapid and potent abrogation of MYC gene transcription by representative small molecule inhibitors of the BET family of chromatin adaptors. MYC transcriptional suppression was observed in the context of the natural, chromosomally translocated, and amplified gene locus. Inhibition of BET bromodomain-promoter interactions and subsequent reduction of MYC transcript and protein levels resulted in G 1 arrest and extensive apoptosis in a variety of leukemia and lymphoma cell lines. Exogenous expression of MYC from an artificial promoter that is resistant to BET regulation significantly protected cells from cell cycle arrest and growth suppression by BET inhibitors. MYC suppression was accompanied by deregulation of the MYC transcriptome, including potent reactivation of the p21 tumor suppressor. Treatment with a BET inhibitor resulted in significant antitumor activity in xenograft models of Burkitt's lymphoma and acute myeloid leukemia. These findings demonstrate that pharmacologic inhibition of MYC is achievable through targeting BET bromodomains. Such inhibitors may have clinical utility given the widespread pathogenetic role of MYC in cancer.
T he BET protein family employs tandem bromodomains to recognize specific acetylated lysine residues in the N-terminal tails of histone proteins (1) . Members of the BET family, including BRD2, BRD3, BRD4, and BRDT, modulate gene expression by recruiting transcriptional regulators to specific genomic locations (1) . BRD4 is a well-established regulator of PTEFb, a complex consisting of cyclin-dependent kinase (CDK) 9 and cyclin T, among other polypeptides (2) (3) (4) . Through its interaction with BRD4, P-TEFb is recruited to promoters to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II (RNAPII). Functional studies have suggested that BRD4 plays an important role in the regulation of growth-associated genes at the M/G 1 boundary by retaining PTEFb at the promoters of key regulatory genes throughout mitosis (3, 4) . Consistent with this model, experimental reduction of BRD4 levels or activity has been shown to cause profound effects on cell cycle progression and cellular viability (3, 4) . BRD2 and BRD3 also regulate the transcription of growthpromoting genes, suggesting that the BET family has reinforcing roles to enable proper cell growth (5) .
The Mitsubishi Tanabe Pharma Corporation first described thienodiazepine analogs that potently inhibit the closely related bromodomains of the BET family (6) . These and related small molecules competitively occupy the acetyl-binding pockets of BET bromodomains, resulting in the release of BET proteins from chromatin (7, 8) . NF-κB-dependent gene expression is one canonical pathway suppressed by BET inhibitors (7) . Accordingly, BET inhibitors were found to be therapeutically effective in preclinical animal models of endotoxic shock caused by activation of Toll-like receptors that trigger the up-regulation of cytokines controlled by NF-κB (7) . Importantly, although RNAimediated depletion of any one individual BET protein has broad effects on transcription, pharmacologic inhibition of the BET bromodomains perturbs the transcription of a narrower range of genes (7) . These findings suggest an opportunity to use BETbromodomain inhibitors to fine-tune key regulatory pathways for therapeutic benefit.
BET inhibitors exhibit anticancer effects in both in vitro and in vivo models of midline carcinoma (8) , a rare but lethal disease that frequently harbors a chromosomal translocation in which the bromodomains of BRD4 are fused to the NUT gene (9) . Although other genetic abnormalities of BET family members in cancer have not been described, we speculated that BET-bromodomain inhibition may have broader utility as an anticancer agent because BRD2, BRD3, and BRD4 are functionally linked to pathways important for cellular viability and cancer signaling.
Results
Leukemia and Lymphoma Cell Lines Are Sensitive to BET-Bromodomain Inhibition. We treated a panel of cancer cell lines by using the recently described BET inhibitor (+)-JQ1 to assess its effects on cellular proliferation. This small molecule is closely related to the Mitsubishi Tanabe compounds and inhibits the individual BET family bromodomains to a similar extent, but does not bind bromodomains from proteins outside of this subfamily (8) . Assessment of cellular viability revealed that (+)-JQ1 had antiproliferative activity in many, but not all, cell lines of various origins (Fig. 1A) . Marked growth inhibition was observed consistently in cell lines derived from patients with leukemia or lymphoma. BET inhibitors have been shown, in stimulated macrophages, to suppress genes in the NF-κB transcriptional pathway (7) that contribute to the pathogenesis of multiple myeloma (10, 11) . Hence, we tested the effects of (+)-JQ1 on a broader set of human myeloma cell lines (HMCL). Fifty percent inhibition of growth (GI 50 ) was seen in 14 of 15 HMCL at concentrations of (+)-JQ1 between 50 and 500 nM ( Fig. 1 A and  B) . To determine whether the observed phenotypes were due to BET-bromodomain inhibition, we treated affected cells with an enantiomer, (-)-JQ1, that has no appreciable binding to BET bromodomains (8) , and detected no effect at high concentrations (Fig. 1B) .
Previous studies using RNAi showed that the BET family member, BRD4, is required for the transition from mitosis to G 1 (3) . Consistent with this observation, the cell cycle profile of LP-1 (HMCL) and Raji (Burkitt's lymphoma; BL) cell lines revealed an increase in the percentage of cells in G 0 /G 1 upon exposure to (+)-JQ1 ( Fig. 1C and Fig. S1 A and B) . To test whether BET inhibitors affect progression through S phase and entry into mitosis, we synchronized AMO-1 (HMCL) cells by using a double thymidine block and released the cells in the presence of DMSO, (+)-JQ1, or (-)-JQ1. We observed no gross defects in the timing of S phase progression or entry into mitosis (Fig.  S1C) . However, at 16 h after release from thymidine, cells grown in the presence of (+)-JQ1 accumulated in G 0 /G 1 , whereas cells grown in (-)-JQ1 or DMSO did not. These data suggest that BET-bromodomain inhibition perturbs cells either during mitosis or at the M/G 1 border, leading to a failure to enter the next cell cycle. Treatment with (+)-JQ1 increased the population of cells in sub-G 1 ( Fig. 1C and Fig. S1 A and B) and induced a significant increase in the number of cells that were Annexin V-positive, suggesting that these cells were undergoing active apoptosis (Fig. 1D) . Therefore, BET bromodomain inhibitors induce cell cycle arrest and apoptosis with a range of sensitivity across a panel of cancer cells.
BET-Bromodomain Inhibition Potently Suppresses MYC Gene Expression. Given the broad activity of the inhibitor in leukemia and lymphoma cells, we sought to define potential mechanisms that could explain the phenotypic responses. Thus, we performed gene expression profiling in LP-1 and Raji cells lines treated with the active and inactive BET inhibitor. We treated cells for 4 and 8 h to identify early, and potentially direct, transcriptional targets of (+)-JQ1. Upon sorting by an average differential expression score representing data across cell lines and time points, the most down-regulated gene was MYC ( Fig. 2A) . MYC ranked at or near the top in each of the individual cell lines and at each time point. Interestingly, LP-1 and Raji cells overexpress MYC by virtue of a chromosomal translocation that fuses the Ig heavy chain locus (IgH) to the promoter proximal region of MYC (12) . The top 20 down-and up-regulated genes in LP-1 and Raji cells according to the differential expression score are shown in Fig.  2A , and the fold changes are reported in Table S1 . At these time points, the transcriptional effects of the inactive BET inhibitor were minor, highlighting the linkage of these effects to the specific binding of (+)-JQ1 ( Fig. 2A) . We used the GSEA program to identify curated gene signatures and transcription factor target genes whose expression changed significantly with BET inhibition (13, 14) . Among the top gene signatures that overlapped with our down-regulated BET signature were gene sets shown to be up-regulated upon over-expression of MYC ( Fig. 2B and Table S2 ). Consistent with this observation, the MYC-MAX DNA binding motif was the top motif gene set repressed by BET inhibition (Fig. 2C and Table S3 ). Collectively, these unbiased expression and computational analyses suggest that suppression of MYC transcription by BET inhibitors results in the deregulation of the MYC transcriptome. A number of HDAC inhibitory gene signatures also overlapped with the BET signature ( Table S2 ). Given that HDAC inhibition blocked the transcriptional affects of BET bromodomain inhibition in the context of NF-κB signaling (7), it will be interesting to test the relationship between BET bromodomain inhibition and HDAC inhibition with respect to MYC suppression. A more comprehensive list of the top gene sets that correlate with BET-bromodomain inhibition is presented in Table S2 and Table S3 .
To define the specificity of MYC suppression in further detail, we treated LP-1 cells with a range of compound concentrations. We observed a dose-dependent suppression of MYC by the active BET inhibitor (Fig. 3A) . Importantly, we observed that the concentrations of (+)-JQ1 required to suppress MYC strongly correlate with the cellular affects on cell cycle arrest and the induction of apoptosis (Fig. S2A) . Exposure of LP-1 cells to a related, but chemically distinct BET inhibitor (7), also resulted in transcriptional suppression of MYC (Fig. S2B ). To determine whether the suppression of MYC by BET-bromodomain inhibition was reversible, we treated LP-1 cells for 2 h with (+)-JQ1 and then removed the inhibitor from the media. We observed a time-dependent restoration of MYC expression to untreated levels by 2 h after washout (Fig. 3B ). We confirmed that MYC was silenced by BET inhibitors in Raji cells, as well as an additional cell line that also contains a chromosomal translocation driving MYC expression, AMO-1 (HMCL) (Fig. S2C) . Thus, MYC expression was markedly suppressed after treatment with (+)-JQ1 in three independent cell lines harboring MYC translocations, suggesting that BET proteins play a key role in IgH-MYC regulation. Expression of MYC was reduced by BET inhibitors within 1 h after treatment (Fig. 4A) , suggesting that BET proteins might be exerting direct effects on the MYC locus. To determine whether BET proteins bind directly to the MYC locus, we performed chromatin immunoprecipitation (ChIP) studies by using antibodies against BRD3 and BRD4. We detected specific enrichment of both BRD3 and BRD4 upstream of the P1 promoter of MYC in Raji cells (Fig. S2D) , which is the active promoter in this translocated allele (15) . In the presence of (+)-JQ1, we observed the release of BRD3 and BRD4 from this promoter (Fig. S2D ). In addition, we monitored BRD4 binding at several distinct regions of the MYC locus in LP-1 cells to track where BRD4 may be functioning to regulate MYC gene expression. Enrichment of BRD4 was observed at several locations including both upand downstream of the transcription start site, although BRD4 binding appeared to peak within the P1 promoter of MYC in LP-1 cells (Fig. 3C) . Treatment of these cells with (+)-JQ1 induced the release of BRD4 from the promoter and downstream of the transcription start site (Fig. 3C) . The levels of histone H3 and acetylated H4 were unaffected upon treatment with (+)-JQ1 (Fig. 3D ). Consistent with a role of BRD4 in p-TEFb recruitment, we observed release of CDK9 from the MYC locus upon BET bromodomain inhibition (Fig. 3D) . The specificity of the BRD4 antibody used in these studies was corroborated by (+)-JQ1 mediated release of BRD4 on three additional genes, whereas a gene desert region on chromosome 12 displayed no BRD4 enrichment (Fig. S2E) . These findings collectively indicate that release of BET proteins from chromatin suppresses the transcription of MYC in LP-1 and Raji cells.
MYC Is Suppressed in Diverse Genetic Contexts. To determine whether BET inhibitors can suppress MYC in different genetic contexts, we assessed a panel of cell lines that overexpress MYC by amplification, viral insertion, or in the absence of recognized genetic changes. Reduced MYC transcript levels were observed within 4 h of (+)-JQ1 treatment in cell lines with either MYC amplification or an unamplified, wild-type locus (Fig. S3A) . MYC mRNA was suppressed by 99.8% in the AML cell line MV4-11, which harbors a wild-type locus (Fig. S3A ). Reflecting this reduction in MYC transcript levels in cell lines treated with BET inhibitor, the levels of MYC protein were also decreased ( CCR1  TNFRSF17  ALKBH8  PTAFR  CXCL10  CD180  SLC16A6  C1orf163  ADAT2  RGS1  C1orf107  SLAMF7  ZNF487  PRDM10  AMKRD37  FJX1  ZMYND8  CD48  MYB  HIST2H2BF  HIST1H2BJ  OR2B6  ATP1B1  HEXIM1  SAT1  CSRNP2  HIST1H2AG  HIST1H2BD  SLFN5  NXF1  HIST2H2BE  SESN3  WDR47  TXNIP  POLR2A with other cell lines (Fig. S3) . Thus, whereas BET inhibitors measurably suppress MYC transcription in the context of translocation, amplification, or with an unaltered, wild-type MYC locus, cells exhibit a range of sensitivity to BET-inhibitor-dependent MYC suppression. Given the known proliferative activity of MYC, transcriptional reprogramming via MYC suppression may significantly contribute to the growth inhibitory effects mediated by BET bromodomain inhibition. Consistent with the observed defects in cell cycle progression, a number of key G 1 -associated cell cycle genes were deregulated in LP-1 cells after 4 and 8 h of treatment with (+)-JQ1. The p21 tumor suppressor, a potent CDK inhibitor, was dramatically reactivated in LP-1 cells upon (+)-JQ1 treatment (Fig. 4A) . Numerous studies have established that MYC represses p21 transcription through its physical association with MIZ1 (16, 17) . We therefore performed a time-course experiment to evaluate whether MYC suppression was coincident with p21 reactivation. Within 1 h of (+)-JQ1 treatment, MYC mRNA was diminished and a concomitant 10-fold induction of p21 was observed (Fig. 4A) . By 4 h, MYC was suppressed by 98% and p21 was reactivated by nearly 400-fold (Fig. 4A) .
To test more directly whether MYC mediates the cell cycle arrest facilitated by BET inhibitors, we made use of a tetracycline-inducible MYC expression construct that is resistant to the effects of BET-bromodomain inhibition ( Fig. 4B and Fig. S4A ). This construct was stably transduced into LP-1 cells, which were then grown in the presence or absence of doxycycline to induce MYC expression for 3 d. (+)-JQ1 or (-)-JQ1 was then added to the cells, and various phenotypes were assessed. After 4 h of treatment with (+)-JQ1, we observed that the robust induction of p21 was strongly attenuated in the presence of exogenous MYC (Fig. 4B ). Similar neutralization of (+)-JQ1-induced transcriptional deregulation was observed for several other genes known to be downstream targets of MYC ( Fig. S4 B and C). Consistent with these transcriptional changes, after 24 h of treatment we noticed a striking rescue of (+)-JQ1-induced G 1 arrest in the presence of exogenous MYC (Fig. 4 C and D) . Although our observations at longer time points were somewhat confounded by the induction of apoptosis with extended periods of MYC overexpression ( Fig. S4D ), we observed a significant protection (P < 0.001) from BET inhibitor-mediated growth suppression by exogenous expression of MYC after 4 d (Fig. 4E ). Taken together, these observations strongly support the conclusion that MYC down-regulation is a primary cause of the growth inhibition observed with BET inhibitors in tumor cells driven by deregulated MYC.
BET Inhibitors Display Antiproliferative Effects in Animal Models of BL
and Acute Myeloid Leukemia (AML). To further investigate the antitumor effects of BET inhibition, we explored xenograft models of BL and AML. Raji (BL) or MV4-11 (AML) cells were grown s.c. in immunocompromised mice, and (+)-JQ1 was administered i.p. either twice a day at 30 mg/kg, or once a day at 50 mg/kg. As shown in Fig. 5A , Raji BL tumors grew significantly slower in compound-treated mice compared with vehicle-treated controls. In this model, the average tumor volume was 45% smaller in the compound-treated group at day 14 ( Fig. 5A ). After this time, survival in the vehicle group was significantly decreased and, therefore, tumor size could not be adequately compared because of the increasingly unequal number of animals between the groups resulting from high tumor-related mortality in the control group. Tumor growth to an average of 1,000 mm 3 was delayed by 7 d in the treatment group compared with the vehicle control group. Consistently, pharmacodynamic analysis indicated that MYC mRNA expression was reduced in Raji tumors by 80% at 4 h and 60% at 8 h after dosing at 25 mg/kg (Fig. 5B ). (+)-JQ1 treatment led to a highly significant increase in survival in the treatment group (Fig. 5C ). One of 15 animals in the treatment group was euthanized because of a large tumor volume. Treatment with (+)-JQ1 in a disseminated model of Raji BL (18) also resulted in significant antitumor activity without weight loss or any other obvious adverse systemic effects ( Fig. S5 A and B) .
In addition to BL, MV4-11 AML xenografts were observed to be particularly sensitive to (+)-JQ1 treatment. In the AML xenograft model, (+)-JQ1 dosed twice daily at 30 mg/kg resulted in a 20% tumor regression when the study was terminated after 32 d of treatment (Fig. 5D) . A 70% decrease in tumor growth was observed with once-a-day dosing of (+)-JQ1 at 50 mg/kg ( dependence on continuous down-regulation of MYC for efficacy in the context of the pharmacokinetic/pharmacodynamic relationship observed in the Raji BL tumors. Standard-of-care agent cytarabine was modestly effective with a 33% decrease in tumor growth (Fig. 5D ). (+)-JQ1 was generally well tolerated throughout the course of all three studies ( Fig. S5 C and D) . Lack of systemic effects was not attributable to an inability of (+)-JQ1 to repress murine MYC, as treatment of the mouse cell lines EL4 and RAW264.7 with (+)-JQ1 resulted in substantial MYC suppression (Fig. S5E ). These data demonstrate significant in vivo antitumor activity linked to BET inhibition and suggest a potential therapeutic use for small molecule inhibitors of BET for the treatment of hematological malignancies.
Discussion
We provide evidence that MYC gene expression can be potently and reversibly abrogated by BET bromodomains inhibitors. Transcriptional silencing of MYC is coincident with release of BET proteins from the MYC locus, indicating that BET proteins directly regulate MYC gene expression. Although BET inhibitors influence the expression of an assortment of genes, the MYC transcriptome heavily dominates the gene expression changes observed upon BET-bromodomain inhibition. The MYC gene is translocated in all patients with BL and a significant fraction of patients with multiple myeloma or diffuse large B-cell lymphoma (19) . BL is well established to depend on the functions of MYC (15, 19) . We observed that several cell lines harboring MYC translocations are sensitive to BET inhibitors as measured by both transcriptional effects and apoptotic responses (Fig. 1, Fig.  S2 , and Fig. S3 ), perhaps reflecting their degree of MYC addiction (20) . Apart from the special case of midline carcinoma, we have yet to observe a cell type that is sensitive to BET inhibitors without down-regulation of MYC (Fig. S6A) . However, MYC reduction did not always correlate with a cell proliferation phenotype in vitro. For example, MYC protein was significantly reduced in the breast cancer cell line MDA-MB-231, which nevertheless grew normally upon administration of (+)-JQ1 ( Fig. 1A and Fig. S3B ). Previous studies have indicated that the in vitro proliferation of the MDA-MB-231 cell line is only mildly affected by a severe reduction of MYC protein by shRNA (21) .
To corroborate this observation, we infected MDA-MB-231 cells with four different shRNAs that knockdown MYC mRNA and assessed their effect on proliferation. As shown in Fig. S6B , MDA-MB-231 cells are not phenotypically sensitive to MYC knockdown by shRNA at comparable mRNA knockdown levels to (+)-JQ1-mediated suppression of MYC. No gross toxicity was observed upon high-dose treatment of BET inhibitors in this MYC-insensitive cell line, revealing no marked, general MYCindependent effects on cellular viability in this setting. Suppression of MYC by BET inhibitors was not observed in every cell line tested, and the degree of MYC silencing also varied at the time points tested. It is possible that variation in the permeability and efflux of BET inhibitors across cell lines contributes to some of these observations. Conceptually, it will be important to elucidate in detail the chromatin or regulatory contexts that define MYC sensitivity to BET inhibitors. These regulatory features may ultimately identify the patients who will respond best to this class of small molecule inhibitors. MYC is a member of a related family of transcription factors that also includes MYCN and MYCL (22, 23) . MYCN and MYCL are both intimately linked to the oncogenic phenotype by means of their genomic translocation, amplification, and overexpression in human tumors. Notably, MYCN is frequently amplified and overexpressed in human neuroblastoma and is functionally believed to be a driver of this disease (23) . High-dose, transient treatment of various cell lines harboring MYCN amplification and overexpression with (+)-JQ1 resulted in the transcriptional suppression of MYCN, although the responses were less pronounced than previously observed for MYC in some contexts (Fig. S6C) . Although the range of responses varies, multiple members of the MYC family appear to be vulnerable to BETbromodomain inhibition, perhaps reflecting a common tran- scriptional regulatory mechanism. Considering the importance of MYCN in neuroblastoma, the study of BET inhibitors in this cancer subtype warrants further exploration. Finally, at doses of (+)-JQ1 that suppressed MYC in tumor cells, repeated treatment in vivo did not result in weight loss or gross adverse effects in the animals used in these studies. These results are consistent with previous findings (8), perhaps suggesting that normal tissues may be relatively resistant to MYC suppression or loss of MYC function, at least during this time course. Future studies examining MYC suppression by BET inhibitors in normal regenerative tissues will be critical for defining the therapeutic applicability of these types of small molecule inhibitors, as will the development of compounds optimized for in vivo applications including medical uses. Inhibitors of BET bromodomains open a new avenue for probing the complex MYC-dependent and MYC-independent regulatory pathways in cancer cells and hold promise as a novel therapeutic for human cancer. Cell number and cell cycle data were obtained by using a Guava Easycyte flow cytometer using the Express Pro module. DNA content histograms were analyzed by using ModFit LT 3.2 Software (Verity). To calculate the number of viable cells in each well, the concentration of events measured using the Guava was multiplied by the volume of cells in the well, then by the fraction of cells in G 1 +S+G 2 /M. GI 50 values for each cell line were calculated as the concentration of compound giving a 50% reduction in cell number relative to the DMSO control. Gene Expression Profiling. LP-1 and Raji cells were treated with (+)-JQ1 or (-)-JQ1 at 500 nM for 4 or 8 h. Total RNA was prepared by using a Qiagen RNEasy kit with on-column DNase digestion according to the manufacturer's instructions. Further processing of samples and data acquisition were performed at ALMAC Diagnostics. Total RNA was amplified by using the Applause WT Amp Plus ST Amplification System (NuGEN) according to the manufacturer's instructions. A modification step targeting the amplified single-stranded cDNA resulted in the generation of sense target (ST) cDNA product compatible with the Affymetrix GeneChip Exon arrays. The ST-cDNA was purified for accurate quantitation and to ensure optimal performance during the fragmentation and labeling process. The appropriate amount of amplified ST-cDNA was fragmented and labeled by using the NuGEN Encore Biotin Module. The fragmented and labeled ST-cDNA was added to the hybridization mixture in accordance with the NuGEN guidelines for hybridization onto GeneChip Exon 1.0 ST arrays (Affymetrix). Hybridization, washing, and array scanning were performed according to the manufacturer's instructions. CEL files were processed by the Affymetrix Expression Console software package by using the gene-level RMA algorithm on the core set of probesets and the annotation file Huex-1_0-st-v2_na31_hg19 provided by Affymetrix. Detailed data analysis methods are available below.
Rescue Experiments. TET activator (pRETROX tet on advanced) and expression constructs (pRETROX tight puro luciferase/myc) were introduced into cells by viral transduction or FuGENEmediated transfection. After selection, doxycycline was added for 3 d and the cells were plated on 96-well plates containing a titration of compound as indicated. Viability and cell cycle distribution were assessed as described above.
Cell Lysates and Western Blotting. Cells were harvested to obtain whole-cell extracts by the addition of one volume of 250 mM Tris·HCl (pH 6.8), 20% glycerol, 2% SDS, 5% 2-mercaptoethanol, and 0.2% bromophenol blue to cells in one volume of PBS followed by boiling for 5 min. Samples were resolved on SDS/PAGE gels and transferred to PVDF membranes. Blots were probed with antibodies to c-MYC (Cell Signaling) and vinculin (Sigma). After incubation with secondary antibodies (Jackson Immunoresearch or ThermoFisher), blots were developed with ECL reagent (Perkin-Elmer) or analyzed on an Odyssey infrared imaging system (Licor).
Chromatin Immunoprecipitation (ChIP) Assays. Samples for ChIP analysis were prepared by cross-linking cells with 1% formaldehyde for 5 min at RT. Cross-linking reactions were quenched by addition of glycine to a final concentration of 0.125 M. Cells were washed with cold PBS and resuspended in lysis buffer (10 mM Tris·HCl, pH 7.4, 10 mM NaCl, 5 mM MgCl 2 , and 0.2% Nonidet P-40). After 1 h of incubation with rotation at 4°C to lyse cells, nuclei were pelleted and resuspended in glycerol buffer (10 mM Tris·HCl at pH 7.4, 0.1 mM EDTA, 5 mM MgOAc, and 25% glycerol) at a density of 5 × 10 6 cells per mL Genomic DNA was fragmented to a size of 200-600 bp by treatment with micrococcal nuclease (Roche). Nuclease digestions were stopped by addition of EDTA to a final concentration of 10 mM. Lysates were centrifuged to pellet debris and were precleared with protein A or G beads that had been blocked with BSA and sheared salmon sperm DNA. Precleared lysates were then used for immunoprecipitations with the following antibodies: H4 tetra-acetyl (Active Motif), H3K4me3 (Abcam), H3 (Abcam), BRD3 (Bethyl), BRD4 (Bethyl), CDK9 (Santa Cruz Biotechnology), and RSF (Millipore). After overnight incubation at 4°C with rotation, protein A or G beads were added and incubated 1 h at 4°C with rotation. Beads were pelleted and washed once with low salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris·HCl at pH 8, and 150 mM NaCl), once with high salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris·HCl at pH 8, and 500 mM NaCl), once with LiCl buffer (0.25 M LiCl, 1% Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, and 10 mM Tris-HCl at pH 8) and twice with T.E. (10 mM Tris at pH 8 and 1 mM EDTA). Samples were eluted from beads by two 15-min incubations at RT with elution buffer (1% SDS and 100 mM NaHCO 3 ). Elutions were pooled, and NaCl were added to a final concentration of 0.2 M. After 4 h at 65°C, DNA was purified from samples by using QIAquick PCR Purification Kit (Qiagen). Purified DNA was used in PCRs with primers in the MYC promoter region.
ChIP analysis was also performed by Active Motif (Fig. S4 ) to qualify the BRD4 antibody. ChIPs were performed as described below for these experiments. Cells were fixed with 1% formaldehyde for 15 min and quenched with 0.125 M glycine. Chromatin was isolated by adding lysis buffer, followed by disruption with a Dounce homogenizer. Lysates were sonicated, and the DNA was sheared to an average length of 300-500 bp. Genomic DNA (Input) was prepared by treating aliquots of chromatin with RNase, proteinase K, and heat for decross-linking, followed by ethanol precipitation. Pellets were resuspended, and the resulting DNA was quantified on a NanoDrop spectrophotometer.
Extrapolation to the original chromatin volume allowed quantitation of the total chromatin yield.
An aliquot of chromatin (25 μg) was precleared with protein A agarose beads (Invitrogen). Genomic DNA regions of interest were isolated by using 4 μg of antibody against BRD4. After incubation at 4°C overnight, protein A agarose beads were used to isolate the immune complexes. Complexes were washed, eluted from the beads with SDS buffer, and subjected to RNase and proteinase K treatment. Cross-links were reversed by incubation overnight at 65°C, and ChIP DNA was purified by phenol-chloroform extraction and ethanol precipitation.
Quantitative PCRs (qPCRs) were carried out in triplicate on specific genomic regions by using SYBR Green Supermix (BioRad). The resulting signals were normalized for primer efficiency by carrying out qPCR for each primer pair using Input DNA. Primer sequences are available upon request.
Quantitative PCR. RNA was purified from cells by using an RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. First-strand cDNA was synthesized by using SuperScript III reverse transcriptase. Quantitative real-time PCR was performed by using FastStart Universal Probe master mix (Roche) and universal probe library probes (Roche) on a Roche Lightcycler 480 II or Stratagene MxPro3005p. Samples were normalized by using β2 microglobulin or GAPDH primer/probe sets. Primer sequences are available upon request. , when body weight decreased >20% of initial weight, or when the mice were in poor health as established in the IACUC protocol. Survival was plotted and analyzed in GraphPad Prism software, and statistical significance was calculated by using log-rank (Mantel-Cox) and GehanBreslow-Wilcoxon tests. MV4-11 xenografts were established in nude mice injected with 10 × 10 6 cells per mouse. JQ1 was dosed i.p. and formulated as described above. Mice were divided into 4 groups of 10 animals: vehicle control once a day; 50 mg/kg (+)-JQ1 once a day; 30 mg/kg (+)-JQ1 twice a day; and cytarabine 100 mg/kg daily (5 d on, 2 d off). Treatment of mice with cytarabine at 100 mg/kg resulted in significant weight loss at day 8 and, therefore, the dose needed to be decreased to 75 mg/kg. Mice were euthanized by CO 2 exposure. Tumor volume data were collected and analyzed as described above. All animal work was performed according to approved IACUC protocols at Vivisource or at WuXi. points after treatment, tumors were harvested. RNA was isolated by using TRIzol extraction and processed for qPCR analysis.
Gene Expression Analysis. CEL files were processed by using Affymetrix Expression Console program (http://media.affymetrix. com/support/downloads/manuals/expression_console_exon_level_ quickstart_guide.pdf) and, specifically, the gene-level RMA algorithm using the core set of probesets. Data were exported from Expression Console by using the function "Export Probe Set Results (pivot table) with Annotations to TXT"; version Huex-1_ 0-st-v2_na31_hg19 annotation files were downloaded from Affymetrix via the Expression Console program. Differential expression scores were calculated separately for the BET inhibitor vs. the inactive enantiomer, at timepoints 4 and 8 h, and for two cell lines (LP-1 and Raji). The differential score for any given cell line and time point was
Where μ active is the mean of the two log-expression values after treatment with the active compound, μ inactive is the same for the inactive compound, σ active is the SD of the two log-expression values after treatment with the active compound, and σ inactive is the same for the inactive compound. This score captures the fold change (or, in log space, the difference) between the expression values after the two compound treatments, while also adjusting for noise: For measurements with a lot of noise (high SDs), the score will have a lower magnitude. The four scores were averaged to create an overall score indicating the differential expression across cell lines and timepoints. Before GSEA analysis, the dataset was filtered to remove transcripts of genes for which there was a higher-expressed transcript in the dataset.
The complete list of genes along with their overall score was used as input to GSEA [Subramanian et al. (3) and Mootha et al. (4) ]. We focused on two of the five major MSIGDB collections: c2 (curated gene sets) and c3 (motif gene sets). We used the following parameters in running GseaPreranked:
MYC shRNAs and Lentiviral Transduction. Target sequences for human c-MYC (NM_002467.4) were obtained from Cellecta. Sense and antisense oligonucleotides (66 nt) containing sense, loop, and antisense sequences were obtained with 5′ phosphorylation from Integrated DNA Technologies. Oligonucleotides were annealed and ligated into a lentiviral shRNA vector based on pLKO.1 obtained from Cellecta. In this vector, shRNA expression is driven by the U6 promoter, and both a fluorescence marker and puromycin acetyltransferase (separated by the T2A sequence) are driven by the UbiC promoter. The target sequences of the shRNAs shown in the text are shRNA 1: 5′-GTCCTGAG- CAATCACCTATGA-3′; shRNA 2: 5′-CCTGAGCAATCACC-TATGAAC-3′; shRNA 3: 5′-CGACGAGAACAGTTGAAAC-AC-3′; and shRNA 4: 5′-GACGAGAACAGTTGAAACACA-3′. The sequence of the nontargeting control shRNA (NTC) is 5′-CGCTGAGTACTTCGAAATGTC-3′. Lentiviral production was carried out according to publicly available protocols (http://www. broadinstitute.org/rnai/public/resources/protocols). For lentiviral transduction and assessment of growth inhibition, LP-1 and MDA-MB-231 cells were transduced with virus at a multiplicity of infection (MOI) that gave 20-60% infection, as measured by determining the percentage of green cells at 24 h after infection. At 4-5 d, the percentage of green cells was measured again, and the ratio of % green cells at 4 d to % green cells at 1 d was calculated. In parallel, cells were transduced at a high MOI, selected with puromycin for 2 d, and RNA was prepared for determination of MYC mRNA expression as described above.
QuantiGene Assay. LP-1 cells were seeded in a 96-well plate and incubated in the presence of various concentrations of (+)-JQ1 for 4 h. Relative mRNA levels were quantitated by using QuantiGene 2.0 assay (Affymetrix) according to the manufacturer's recommendation. Signals were detected by using an Envision plate reader (Perkin-Elme). Biological duplicates were averaged and normalized to vehicle (DMSO) control to calculate percent MYC mRNA levels. 
